Yahoo · Sep 8, 2026
Are Medical Stocks Lagging CareDx (CDNA) This Year?
Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.
CD
NASDAQ · CDNA
CareDx, Inc
Healthcare · Medical - Diagnostics & Research
$52.37
Up+$2.11 (+4.20%)
Updated Sep 15, 2026, 6:20 AM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.02B
- P/E ratio
- 17.11
- Dividend yield
- 0.00%
- 52-week range
- $15.56 – $53.67
- Volume
- 795.53K
- Avg. volume
- 1.12M
Price performance
CDNA price history
1M range · 20 trading sessions · Daily adjusted prices
CDNA closed at $52.37 after 20 trading sessions, up 12.92% for the selected period.
- Last close
- $52.37
- Period change
- +12.92%
- Period low
- $46.18
- Period high
- $52.37
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 14, 2026 | $50.49 | $52.67 | $50.17 | $52.37 | 795.53K |
| Sep 11, 2026 | $50.14 | $50.85 | $49.57 | $50.26 | 663.05K |
| Sep 10, 2026 | $49.19 | $51.69 | $48.64 | $50.02 | 1.61M |
| Sep 9, 2026 | $49.875 | $51.33 | $49.64 | $50.03 | 1.22M |
| Sep 8, 2026 | $50.50 | $50.87 | $49.46 | $50.31 | 935.08K |
| Sep 4, 2026 | $49.65 | $50.99 | $48.68 | $50.88 | 1.31M |
| Sep 3, 2026 | $49.75 | $50.50 | $48.3856 | $49.86 | 636.77K |
| Sep 2, 2026 | $49.55 | $51.37 | $48.40 | $49.60 | 826.21K |
| Sep 1, 2026 | $49.93 | $50.62 | $48.2501 | $48.97 | 1.25M |
| Aug 31, 2026 | $49.16 | $50.28 | $46.6879 | $50.11 | 1.53M |
| Aug 28, 2026 | $51.495 | $52.38 | $49.60 | $49.79 | 1.18M |
| Aug 27, 2026 | $51.00 | $53.6712 | $50.765 | $52.36 | 1.25M |
| Aug 26, 2026 | $50.15 | $51.08 | $49.0666 | $50.96 | 1.42M |
| Aug 25, 2026 | $48.13 | $51.125 | $47.234 | $50.80 | 1.79M |
| Aug 24, 2026 | $48.30 | $48.51 | $46.92 | $47.50 | 769.59K |
| Aug 21, 2026 | $46.99 | $48.72 | $46.0497 | $48.61 | 1.16M |
| Aug 20, 2026 | $45.902 | $47.845 | $45.332 | $46.99 | 911.18K |
| Aug 19, 2026 | $46.85 | $48.4299 | $46.41 | $46.51 | 1.89M |
| Aug 18, 2026 | $45.68 | $46.5174 | $44.80 | $46.18 | 840.13K |
| Aug 17, 2026 | $45.325 | $47.075 | $45.02 | $46.38 | 733.14K |
Latest CDNA news
The latest Smart Investors Daily articles mentioning CDNA.
Stock researchCompany · Overview
CDNA research
Overview
Company profile and research snapshot.
Company profile
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $28.80
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | Canaccord Genuity | Buy | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Jul 31, 2026 | HC Wainwright & Co. | Neutral | — |
| Jul 16, 2026 | BTIG | Buy | — |
| Apr 29, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
ChartMill · Sep 5, 2026
CareDx (NASDAQ:CDNA) Screens Well on High Growth Momentum and Breakout Setup
CareDx (CDNA) shows high growth momentum with accelerating sales and earnings, plus a 10 technical rating. Breakout setup near $53.68.
Benzinga · Sep 2, 2026
Canaccord Genuity Initiates Coverage On CareDx with Buy Rating, Announces Price Target of $65
Canaccord Genuity analyst Kyle Mikson initiates coverage on CareDx (NASDAQ:CDNA) with a Buy rating and announces Price Target of $65.
ChartMill · Aug 28, 2026
CareDx (NASDAQ:CDNA) Shows Strong Growth Fundamentals by Passing All Eight Rules of Navellier's Screen
CareDx (CDNA) passes Louis Navellier's 8 growth rules: strong earnings revisions, sales growth, margins, cash flow, ROE. See why it stands out.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
